Takeda Pharmaceutical Co Ltd
TAKHealthcare|Drug Manufacturers - Specialty & Generic|Japan
$16.56
-0.05 (-0.30%)
DCF (FCF)
$23.41
About
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Stock Price
+11.6%(1Y)
Pipeline Summary
501 total trials104
Phase 1
106
Phase 2
147
Phase 3
47
Phase 4
Completed: 353Terminated: 64Recruiting: 36Withdrawn: 17Active: 19Unknown: 6APPROVED_FOR_MARKETING: 3NOT_YET_RECRUITING: 3
Active Trials (55)
BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe
NCT06856902Cardiovascular Diseases
N/ARecruiting
Enrollment: 3,100 participants
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
NCT05156983Coagulation Disorder
Phase 3Recruiting
Enrollment: 440 participants
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
NCT05879757Multiple Myeloma
Recruiting
Enrollment: 75 participants
A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
NCT07129343Von Willebrand Disease (VWD)
Phase 3Recruiting
Enrollment: 20 participants
A Study of CDPATH™ to Help Manage and Treat Crohn's Disease
NCT04809363Crohn's Disease
Phase 4Active
Enrollment: 200 participants
BioScore
5.4/10
Watchlist
Ownership
Recent News
2026-07-02 22:36:57
2026-06-24 09:52:18
2026-06-24 08:55:27
2026-06-24 08:00:04
2026-06-23 13:33:32
Data last updated: Jul 12, 2026, 07:24 PM